PsyBio Therapeutics Corp. Logo

PsyBio Therapeutics Corp.

PSYBF

(2.2)
Stock Price

0,00 USD

-1251.66% ROA

-867.3% ROE

-0x PER

Market Cap.

30.820.757,00 USD

-8.52% DER

0% Yield

0% NPM

PsyBio Therapeutics Corp. Stock Analysis

PsyBio Therapeutics Corp. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PsyBio Therapeutics Corp. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (408.52%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.31x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-6%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

6 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

7 ROA

The stock's ROA (-1371.55%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

PsyBio Therapeutics Corp. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PsyBio Therapeutics Corp. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

PsyBio Therapeutics Corp. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PsyBio Therapeutics Corp. Revenue
Year Revenue Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PsyBio Therapeutics Corp. Research and Development Expenses
Year Research and Development Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 54.545 100%
2021 622.796 91.24%
2022 390.138 -59.63%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PsyBio Therapeutics Corp. General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 991.944 100%
2021 8.898.273 88.85%
2022 3.947.281 -125.43%
2023 420.332 -839.09%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PsyBio Therapeutics Corp. EBITDA
Year EBITDA Growth
2016 -77.038
2017 -39.849 -93.32%
2018 -20.860 -91.03%
2019 -38.972 46.47%
2020 353 11140.23%
2021 -8.228.208 100%
2022 -4.575.990 -79.81%
2023 -627.968 -628.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PsyBio Therapeutics Corp. Gross Profit
Year Gross Profit Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 -1.534.553 100%
2021 -62.500 -2355.28%
2022 -50.000 -25%
2023 -100.000 50%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PsyBio Therapeutics Corp. Net Profit
Year Net Profit Growth
2016 -56.862
2017 -39.852 -42.68%
2018 -20.861 -91.04%
2019 -16.158 -29.11%
2020 -6.435.657 99.75%
2021 -11.018.878 41.59%
2022 -4.886.063 -125.52%
2023 -727.968 -571.19%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PsyBio Therapeutics Corp. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PsyBio Therapeutics Corp. Free Cashflow
Year Free Cashflow Growth
2016 -67.797
2017 -39.712 -70.72%
2018 -13.914 -185.41%
2019 -24.133 42.34%
2020 -863.760 97.21%
2021 -6.946.036 87.56%
2022 -3.437.030 -102.09%
2023 339.600 1112.08%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PsyBio Therapeutics Corp. Operating Cashflow
Year Operating Cashflow Growth
2016 -67.797
2017 -39.712 -70.72%
2018 -13.914 -185.41%
2019 -24.133 42.34%
2020 -863.760 97.21%
2021 -6.949.776 87.57%
2022 -3.437.030 -102.2%
2023 339.600 1112.08%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PsyBio Therapeutics Corp. Capital Expenditure
Year Capital Expenditure Growth
2016 0
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 -3.740 100%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PsyBio Therapeutics Corp. Equity
Year Equity Growth
2016 158.526
2017 169.975 6.74%
2018 150.245 -13.13%
2019 127.991 -17.39%
2020 -736.913 117.37%
2021 2.717.666 127.12%
2022 -1.590.942 270.82%
2023 -1.687.527 5.72%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PsyBio Therapeutics Corp. Assets
Year Assets Growth
2016 255.240
2017 206.089 -23.85%
2018 193.547 -6.48%
2019 161.562 -19.8%
2020 286.496 43.61%
2021 4.008.204 92.85%
2022 390.366 -926.78%
2023 283.143 -37.87%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PsyBio Therapeutics Corp. Liabilities
Year Liabilities Growth
2016 96.714
2017 36.114 -167.8%
2018 43.302 16.6%
2019 33.570 -28.99%
2020 1.023.409 96.72%
2021 1.290.538 20.7%
2022 1.981.308 34.86%
2023 1.970.670 -0.54%

PsyBio Therapeutics Corp. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.04
Price to Earning Ratio
-0x
Price To Sales Ratio
0x
POCF Ratio
-0
PFCF Ratio
-8.97
Price to Book Ratio
-0.01
EV to Sales
0
EV Over EBITDA
-6.76
EV to Operating CashFlow
-9.01
EV to FreeCashFlow
-9.01
Earnings Yield
-437
FreeCashFlow Yield
-0.11
Market Cap
0,03 Bil.
Enterprise Value
0,03 Bil.
Graham Number
0.12
Graham NetNet
-0.02

Income Statement Metrics

Net Income per Share
-0.04
Income Quality
0.7
ROE
-8.67
Return On Assets
-12.52
Return On Capital Employed
3.07
Net Income per EBT
1
EBT Per Ebit
1.03
Ebit per Revenue
0
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.03
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
3.28
Return on Tangible Assets
-12.52
Days Sales Outstanding
0
Days Payables Outstanding
9725.66
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.04
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,01
Tangible Book Value per Share
-0.01
Shareholders Equity per Share
-0.01
Interest Debt per Share
0
Debt to Equity
-0.09
Debt to Assets
0.35
Net Debt to EBITDA
-0.03
Current Ratio
0.13
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1551252
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PsyBio Therapeutics Corp. Dividends
Year Dividends Growth

PsyBio Therapeutics Corp. Profile

About PsyBio Therapeutics Corp.

PsyBio Therapeutics Corp., a biotechnology company, focuses on the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. The company is headquartered in Coconut Creek, Florida.

CEO
Mr. Evan Mike Levine
Employee
4
Address
4400 West Sample Road
Coconut Creek, 33073

PsyBio Therapeutics Corp. Executives & BODs

PsyBio Therapeutics Corp. Executives & BODs
# Name Age
1 Mr. Noah Isidore Davis
Chief Financial Officer, Secretary & Director
70
2 Mr. Andrew Jones
Inventor & Chairman of Scientific Advisory Board
70
3 Mr. Ross Carmel
Chief Legal Officer & Director
70
4 Mr. Evan Mike Levine
Co-Founder, Chief Executive Officer & Chairman
70
5 Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D.
Chief Scientific Officer & Chief Medical Officer
70

PsyBio Therapeutics Corp. Competitors